John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
News|Articles|July 3, 2025
FDA news recap in urology for Q2 2025
Fact checked by: Patrick Campbell
Here’s a look back at notable news between April and June 2025.
Advertisement
Advertisement
The specialty of urology, following an eventful first quarter, had a busy Q2 with a flurry of FDA approvals (and 1 notable non-approval) ranging from benign prostatic hyperplasia (BPH) to urge incontinence to bladder cancer and prostate cancer.
Related to this article
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement